SOX2 and breast cancer: Furthermore, for the first time, we have developed and characterized a novel monoclonal antibody against Sox2 phosphorylation at T116 site, which can be used as a surrogate potential marker to identify more tumorigenic and cancer stem-like subpopulation in BC.